vs
Side-by-side financial comparison of AMERICAN STATES WATER CO (AWR) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $164.3M, roughly 1.1× AMERICAN STATES WATER CO). AMERICAN STATES WATER CO runs the higher net margin — 17.5% vs 1.6%, a 15.9% gap on every dollar of revenue. On growth, AMERICAN STATES WATER CO posted the faster year-over-year revenue change (14.8% vs 5.0%). Over the past eight quarters, AMERICAN STATES WATER CO's revenue compounded faster (10.2% CAGR vs -0.2%).
American Water is an American public utility company that, through its subsidiaries, provides water and wastewater services in the United States.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
AWR vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $164.3M | $177.4M |
| Net Profit | $28.7M | $2.9M |
| Gross Margin | 88.9% | — |
| Operating Margin | 27.4% | 3.9% |
| Net Margin | 17.5% | 1.6% |
| Revenue YoY | 14.8% | 5.0% |
| Net Profit YoY | 1.1% | — |
| EPS (diluted) | $0.74 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $164.3M | $196.9M | ||
| Q3 25 | $182.7M | $179.5M | ||
| Q2 25 | $163.1M | $181.1M | ||
| Q1 25 | $148.0M | $168.9M | ||
| Q4 24 | $143.1M | $187.3M | ||
| Q3 24 | $161.8M | $168.6M | ||
| Q2 24 | $155.3M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $28.7M | — | ||
| Q3 25 | $41.2M | $5.4M | ||
| Q2 25 | $33.7M | $-4.8M | ||
| Q1 25 | $26.8M | $4.8M | ||
| Q4 24 | $28.4M | — | ||
| Q3 24 | $35.8M | $-143.5M | ||
| Q2 24 | $31.9M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 88.9% | 79.5% | ||
| Q3 25 | 91.0% | 80.9% | ||
| Q2 25 | 92.1% | 77.4% | ||
| Q1 25 | 91.3% | 79.7% | ||
| Q4 24 | 92.4% | 78.7% | ||
| Q3 24 | 92.7% | 76.9% | ||
| Q2 24 | 89.6% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 27.4% | 1.2% | ||
| Q3 25 | 33.8% | 3.5% | ||
| Q2 25 | 31.3% | 4.7% | ||
| Q1 25 | 30.8% | 1.2% | ||
| Q4 24 | 27.0% | 13.2% | ||
| Q3 24 | 34.0% | -82.8% | ||
| Q2 24 | 33.3% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 17.5% | — | ||
| Q3 25 | 22.5% | 3.0% | ||
| Q2 25 | 20.7% | -2.7% | ||
| Q1 25 | 18.1% | 2.8% | ||
| Q4 24 | 19.9% | — | ||
| Q3 24 | 22.1% | -85.1% | ||
| Q2 24 | 20.5% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.74 | $0.05 | ||
| Q3 25 | $1.06 | $0.12 | ||
| Q2 25 | $0.87 | $-0.11 | ||
| Q1 25 | $0.70 | $0.10 | ||
| Q4 24 | $0.75 | $0.38 | ||
| Q3 24 | $0.95 | $-3.11 | ||
| Q2 24 | $0.85 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $18.8M | $144.3M |
| Total DebtLower is stronger | $782.7M | — |
| Stockholders' EquityBook value | $1.0B | $653.9M |
| Total Assets | $2.7B | $1.2B |
| Debt / EquityLower = less leverage | 0.75× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $18.8M | $238.4M | ||
| Q3 25 | $26.1M | $246.3M | ||
| Q2 25 | $20.2M | $445.9M | ||
| Q1 25 | $21.2M | $493.6M | ||
| Q4 24 | $26.7M | $484.6M | ||
| Q3 24 | $16.5M | $453.8M | ||
| Q2 24 | $3.6M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $782.7M | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | $640.4M | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $1.0B | $693.1M | ||
| Q3 25 | $1.0B | $727.2M | ||
| Q2 25 | $972.5M | $757.8M | ||
| Q1 25 | $956.4M | $798.5M | ||
| Q4 24 | $920.1M | $778.3M | ||
| Q3 24 | $879.5M | $749.6M | ||
| Q2 24 | $833.5M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $2.7B | $1.3B | ||
| Q3 25 | $2.7B | $1.3B | ||
| Q2 25 | $2.6B | $1.5B | ||
| Q1 25 | $2.5B | $1.6B | ||
| Q4 24 | $2.5B | $1.6B | ||
| Q3 24 | $2.4B | $1.5B | ||
| Q2 24 | $2.3B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 0.75× | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | 0.70× | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $27.7M | — |
| Free Cash FlowOCF − Capex | $-36.0M | — |
| FCF MarginFCF / Revenue | -21.9% | — |
| Capex IntensityCapex / Revenue | 38.8% | — |
| Cash ConversionOCF / Net Profit | 0.96× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-7.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $27.7M | $43.7M | ||
| Q3 25 | $92.4M | $60.8M | ||
| Q2 25 | $64.6M | $12.0M | ||
| Q1 25 | $45.1M | $35.5M | ||
| Q4 24 | $64.5M | $33.1M | ||
| Q3 24 | $63.7M | $53.9M | ||
| Q2 24 | $24.7M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $-36.0M | $43.5M | ||
| Q3 25 | $37.7M | $57.0M | ||
| Q2 25 | $13.7M | $9.3M | ||
| Q1 25 | $-22.5M | $26.9M | ||
| Q4 24 | $6.0M | $31.0M | ||
| Q3 24 | $-478.0K | $49.8M | ||
| Q2 24 | $-37.0M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | -21.9% | 22.1% | ||
| Q3 25 | 20.7% | 31.7% | ||
| Q2 25 | 8.4% | 5.1% | ||
| Q1 25 | -15.2% | 15.9% | ||
| Q4 24 | 4.2% | 16.6% | ||
| Q3 24 | -0.3% | 29.6% | ||
| Q2 24 | -23.8% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 38.8% | 0.1% | ||
| Q3 25 | 29.9% | 2.2% | ||
| Q2 25 | 31.2% | 1.5% | ||
| Q1 25 | 45.6% | 5.1% | ||
| Q4 24 | 40.9% | 1.1% | ||
| Q3 24 | 39.7% | 2.4% | ||
| Q2 24 | 39.8% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 0.96× | — | ||
| Q3 25 | 2.24× | 11.20× | ||
| Q2 25 | 1.92× | — | ||
| Q1 25 | 1.68× | 7.37× | ||
| Q4 24 | 2.27× | — | ||
| Q3 24 | 1.78× | — | ||
| Q2 24 | 0.78× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AWR
| Water Service Utility Operations | $110.0M | 67% |
| Public Utilities Inventory Water | $22.3M | 14% |
| Wastewater | $15.9M | 10% |
| Electric Service Utility Operations | $15.2M | 9% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
